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Abstract: Apolipoprotein (apo) AI and apoB are the major apolipoproteins of high-density 
lipoprotein (HDL) and low-density lipoprotein (LDL), respectively. ApoB assembles the pre-
cursor of LDL, very-low-density lipoprotein (VLDL), in the liver. The assembly starts with 
the formation of a primordial particle, which is converted to VLDL2. The VLDL2 particle is 
then transferred to the Golgi apparatus and can either be secreted or converted to triglyceride-
rich VLDL1. We have reviewed this assembly process, the process involved in the storage of 
triglycerides in cytosolic lipid droplets, and the relationship between these two processes. We 
also brieﬂ  y discuss the formation of HDL. ApoB mediates the interaction between LDL and the 
arterial wall. Two regions in apoB are involved in this binding. This interaction and its role in 
the development of atherosclerosis are reviewed. ApoB can be used to measure the number of 
LDL or VLDL particles present in plasma, as there is one molecule of apoB on each particle. 
By contrast, the amount of cholesterol and other lipids on each particle varies under different 
conditions. We address the possibility of using apoAI and apoB levels to estimate the risk of 
development of cardiovascular diseases and to monitor intervention to treat these diseases.
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Introduction
Cardiovascular diseases are increasing in prevalence and represent a major public health 
burden of the 21st century. Atherosclerosis is the major cause of these diseases and 
several risk factors have been identiﬁ  ed that promote the development of premature 
atherosclerosis. In a large, international, case-control study (INTERHEART), abnor-
mal plasma lipoproteins have been shown to be a major risk factor for myocardial 
infarction (Yusuf et al 2004).
Several types of lipoprotein have been identiﬁ  ed in plasma. They are usually 
separated according to their hydrated density into high-density lipoprotein (HDL) 2 
and 3 , low-density lipoprotein (LDL), intermediate-density lipoprotein, very-low-
density lipoprotein (VLDL) 1 and 2, and chylomicrones (the plasma lipoproteins and 
their composition are reviewed in most modern biochemistry textbooks). VLDL is 
secreted from the liver and is the precursor of LDL. The conversion of VLDL to LDL 
is a complex process that has been modeled in vivo in humans both under normal 
conditions and in diseases (reviewed in (Adiels et al 2006)).
Apolipoproteins are the protein components of plasma lipoproteins and several 
different apolipoproteins have been identiﬁ  ed. The major apolipoprotein of LDL is 
apoB100, which is synthesized in the liver and enters the plasma with VLDL. There 
is one apoB100 molecule on each LDL particle, and it is used to estimate the number 
of LDL and VLDL particles present in plasma. In this aspect, apoB100 is superior 
to LDL cholesterol or non-HDL cholesterol as the cholesterol content on the LDL Vascular Health and Risk Management 2007:3(4) 492
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and VLDL particles can vary considerably. The two major 
proteins in HDL are apoAI and apoAII. Of these, apoAI has 
most frequently been used to estimate the HDL levels but, in 
contrast to apoB100, it exchanges between lipoproteins and 
the number of molecules varies between particles.
In this article, we have reviewed how apoB100 assembles 
VLDL in the liver and how the protein interacts with the arte-
rial wall during the development of atherosclerosis. We also 
give a brief summary on the assembly of HDL. Moreover, 
we discuss the possibility of using apoB and apoAI to predict 
the risk of cardiovascular diseases and to monitor the effect 
of intervention to treat such diseases.
Composition of VLDL
VLDL is assembled in and secreted from the liver. There 
are two forms of VLDL: VLDL1, which is large and rich in 
triglycerides, and VLDL2, which is smaller and contains less 
triglycerides. The type of particle that is secreted is highly 
important for the atherogenicity of the plasma lipoproteins. 
Secretion of VLDL1 increases the levels of so-called small 
dense LDL and decreases the levels of HDL, and both of 
these changes have been shown to promote the development 
of atherosclerosis (for review, see (Taskinen 2003)). Over-
production of VLDL1 is observed in patients with insulin 
resistance and type 2 diabetes (Taskinen 2003).
As for all lipoproteins, VLDL consists of a core of neutral 
lipids (triglycerides and cholesterol esters) surrounded by a 
monolayer of amphipathic structures such as phospholipids, 
free cholesterol, and proteins. ApoB100 is a large (4536 
amino acid long) amphipathic protein that is present on 
VLDL (Segrest et al 2001). It has a pentapartite structure 
consisting of a globular N-terminal domain, two domains 
of amphipathic β-sheets, and two domains of amphipathic 
α-helices, one between the two β-sheet domains and one 
near the C-terminus (Segrest et al 2001). The N-terminal 
domain is of vital importance for the formation of VLDL as 
it interacts with the microsomal triglyceride transfer protein 
(MTP), which catalyzes the transfer of lipids to apoB dur-
ing the formation of lipoproteins (Dashti et al 2002). The 
amphipathic β-sheet domains consist of antiparallel β-sheets 
with a width of approximately 30 Å. They form very strong 
lipid-binding structures (Segrest et al 2001), which is gener-
ally thought to explain why apoB remains associated with 
the original core structure rather than equilibrating between 
different lipoproteins.
The three-dimensional structure of apoB is not known 
in detail, but the overall organization on the LDL has been 
elucidated using immuno-electronmicroscopy (Chatterton 
et al 1995). The protein has an elongated structure that 
encircles the entire particle (Figure 1). The C-terminus folds 
back over the preceding structure; an arginine (residue 3500) 
binds to a tryptophan (residue 4396), which prevents the 
C-terminus from sliding over the binding site for the LDL 
receptor between residues 3359 and 3369 (Figure 1). Mutation 
of the arginine (residue 3500) results in reduced binding to 
the LDL receptor because the arginine–tryptophan interaction 
is broken (Boren et al 2001a; Boren et al 1998a).
In several species, an additional apoB, apoB48 is also 
expressed in the liver, where it forms VLDL of the same type 
as that formed by apoB100. In humans, apoB48 is formed in 
the intestine and assembles chylomicrons.
The assembly of VLDL
ApoB100 is a secretory protein and is synthesized on ribo-
somes attached to the surface of the endoplasmic reticulum 
(Figure 2). During its formation, the “nascent” polypeptide 
is translocated through a channel from the site of synthesis 
in the ribosome through the membrane to the lumen of the 
endoplasmic reticulum (ER). Secretory proteins acquire their 
tertiary structure in the ER by a folding process that depends 
on so-called chaperone proteins. Correctly folded proteins 
are sorted into exit sites to leave the ER by transport vesicles. 
If the correct tertiary structure is not achieved, the protein is 
retained in the ER and retracted through the membrane channel 
and sorted to proteasomal degradation (Ellgaard and Helenius 
2001; Ellgaard and Helenius 2003; Ellgaard et al 1999; John-
son and Haigh 2000; Johnson and van Waes 1999; Kostova 
and Wolf 2003; Lippincott-Schwartz et al 2000).
The formation of vesicles at the exit site depends on the 
GTPase SAR1 and the coat protein coatamere protein II 
(COPII). These vesicles carry the secretory products out of 
the ER and form the ER-Golgi intermediate compartment 
(ERGIC), an organelle that is involved in sorting of proteins. 
Thus, proteins that should remain in the ER are returned to 
this organelle from ERGIC. The sorting process involves 
the formation of vesicles by the GTPase ARF1 and COPI. 
ERGIC is transported to the cis-Golgi and fuses to continu-
ously form this compartment. ARF1 is of importance for the 
ability of ERGIC to mature into cis-Golgi (Nickel et al 1998; 
Nickel and Wieland 1998; Spang 2002) (Figure 2).
VLDL is formed by a stepwise lipidation of apoB100 
occurring as it is transferred through the secretory pathway 
(Figure 2). The process starts during the entry of the N-termi-
nus of apoB100 in the lumen of the ER by an MTP-dependent 
addition of lipid to the growing apoB protein (Figure 2). 
The C-terminal portion of apoB100 breaks this lipidation Vascular Health and Risk Management 2007:3(4) 493
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(Stillemark-Billton et al 2005). An underlipidated primordial 
particle (pre-VLDL) is thus formed that interacts with ER 
chaperones and is either retained in the cell (and subsequently 
degraded) or is further lipidated to form VLDL2. We propose 
that this reﬂ  ects a need to form a VLDL particle that is large 
enough to allow apoB to fold correctly in its surface.
The ability of apoB100 to form pre-VLDL is dependent 
on the sequence between residues 3265 and 4082 (Stillemark-
Billton et al 2005), which introduces a shift in lipidation of the 
protein. This sequence is capable of temporarily switching off 
the lipidation awaiting, for example, the availability of MTP 
and/or lipids. It is possible that this switch is involved in the 
lipid-dependent sorting of apoB100 to secretion or degrada-
tion. Moreover, it seems that the effect of this sequence is 
to promote the binding of chaperones to pre-VLDL (Stille-
mark-Billton et al 2005), which are most likely involved in 
the retention of the particle in the cell. The observation that 
pre-VLDL is converted to VLDL2 by the addition of more 
lipids implies that MTP is also active after the completion 
of apoB100. This ﬁ  ts with our ﬁ  nding that MTP is needed 
for a period after the completion of apoB100 to allow the 
formation of a secretable apoB100 containing lipoproteins 
(Rustaeus et al 1998). Thus, during this period, MTP may 
convert pre-VLDL to VLDL2.
The lipidation of VLDL2 is dependent on the size of apoB, 
and there is an inverse relationship between the density of the 
particle formed and the length of the protein (Stillemark-Bill-
ton et al 2005). A bona ﬁ  de VLDL2 is only formed by apoB100 
while truncated forms of apoB form more dense particles that 
are VLDL2 analogues. For example, apoB48, which is the 
natural occuring truncated form of apoB100, forms a dense 
“HDL-sized” particle that is mature and secreted from the cell, 
unlike the primordial immature particle formed by apoB100. 
The apoB48-containing VLDL2 analogue is formed in the 
ER (Stillemark et al 2000), but it is not known whether the 
apoB100-containing VLDL2 is formed in the ER or after 
apoB has exited this compartment. Assembly of VLDL2 (and 
VLDL2 analogues) in the ER would ﬁ  t with the paradigm that 
only correctly folded proteins are allowed to be transferred to 
the later part of the secretory pathway (Figure 2). (For quality 
Figure 1 The organization of apoB100 on the LDL particle. Two of the sites (A and B) involved in the binding of apoB100 (and LDL) to proteoglycans are indicated in the 
ﬁ  gure and their primary sequence is given below. Site B is also the binding site for the LDL receptor.Vascular Health and Risk Management 2007:3(4) 494
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observation in humans injected with stable amino acid and 
glycerol isotopes: labeled triglycerides were secreted 15 min 
before labeled apoB100 (Adiels et al 2005b). Furthermore, 
we have found evidence of a precursor-product relationship 
between VLDL2 and VLDL1 in clinical turnover studies 
using stable isotopes. Thus, in insulin-clamp studies, we 
observed that insulin decreased the assembly of VLDL1 
and at the same time increased the assembly and secretion 
of VLDL2 (Adiels et al Manuscript in preparation).
Cytosolic lipid droplets
The assembly of VLDL is highly dependent on the amount 
of triglycerides in the hepatocytes. Several authors have 
demonstrated that the fatty acids used for the biosynthesis 
of VLDL triglycerides are derived from triglycerides stored 
in cytosolic lipid droplets (Gibbons et al 2000; Salter et al 
1998; Wiggins and Gibbons 1992). The droplets are now 
recognized as dynamic organelles rather than passive stores 
of lipids (Martin and Parton 2006).
control of folded proteins, see the following reviews (Ahner 
and Brodsky 2004; Ellgaard and Helenius 2001; Ellgaard and 
Helenius 2003; Kleizen and Braakman 2004; Schroder and 
Kaufman 2005; Sitia and Braakman 2003)). We therefore 
propose that the primordial particle that is formed by lipida-
tion of the growing apoB100 must be converted to VLDL2 
before it can leave the ER, and that VLDL2 must reach the 
Golgi apparatus before it can be converted to VLDL1. Both 
VLDL2 and VLDL1 are secreted while the primordial particle 
(pre-VLDL) is retained and eventually degraded.
The formation of VLDL1 involves a bulk lipidation (ie, 
the addition of a major load of triglycerides) of VLDL2 or 
the VLDL2 analogues, and the apoB acceptor is only required 
to have a minimum size of apoB48 (Stillemark-Billton et al 
2005). Both apoB and VLDL2 (or its analogues) must be 
transported to the Golgi apparatus to allow VLDL1 forma-
tion (Asp et al 2005; Stillemark et al 2000). The time gap 
necessary for apoB to be transferred to the Golgi apparatus 
to obtain its major lipidation is in agreement with our recent 
Figure 2 The assembly of VLDL. During its biosynthesis, apoB100 (1) is translocated to the lumen of the endoplasmic reticulum and lipidated by MTP to form a pre-VLDL 
particle (2). Pre-VLDL is further lipidated to form VLDL2 (5). Alternatively, pre-VLDL and misfolded apoB100 (3) can be retained and degraded in the cell (4). The VLDL2 is 
transferred to the Golgi apparatus (6, 7) and is either secreted or further lipidated to form VLDL1 (8). Fatty acids are released from cytosolic lipid droplets and used for the 
formation of triglycerides, which are assembled into VLDL (8).Vascular Health and Risk Management 2007:3(4) 495
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The structure of cytosolic lipid droplets is very similar 
to that of lipoproteins, with a core of neutral lipids sur-
rounded by a monolayer of amphipathic structures such 
as phospholipids, cholesterol, and proteins. The most well 
known of these proteins are the PAT proteins (Londos et al 
1999) perilipin, which is present in adipocytes and cells 
involved in the biosynthesis of steroid hormones, adipocyte 
differentiation-related protein (ADRP), which is ubiquitously 
expressed, and tail-interacting protein 47 (TiP47). There are 
several other proteins with important functions present on the 
droplets (Brasaemle et al 2004; Liu et al 2004).
The lipid droplets are formed as small structures (0.1–0.4 
µm) in or close to the ER and/or Golgi membranes (Marche-
san et al 2003). Insulin promotes the formation of lipid 
droplets via the activation of phospholipase D1 (PLD1) and 
extracellular signal-related kinase 2 (ERK2) (Andersson et al 
2006). ERK2 phosphorylates the motor protein dynein, which 
is then targeted to lipid droplets allowing them to transfer 
to microtubules and increase in size by fusion (Andersson 
et al 2006; Bostrom et al 2005). A model for the assembly 
of lipid droplets is shown in Figure 3.
The importance of triglycerides for the assembly and 
secretion of VLDL is supported by our turnover studies 
in vivo, which demonstrate that the secretion of VLDL1 
apoB100 increases with increasing concentrations of liver 
lipids (Adiels et al 2005a). However, the relationship between 
stored triglycerides and the secretion of VLDL is complex.
On the basis of our results, we conclude that there are at 
least two ways of inﬂ  uencing the pool of lipid droplets in 
the cell: (i) by promoting the formation of small primordial 
droplets and (ii) by promoting the rate of fusion between 
the droplets. We have demonstrated that both mechanisms 
also inﬂ  uence the assembly of VLDL. An increase in ADRP 
results in an increase in the formation of the droplets and the 
pool of the droplets and a subsequent decrease in the assem-
bly of VLDL, in particular VLDL1 (Magnusson et al 2006). 
This is because ADRP promotes the storage of newly formed 
triglycerides in cytosolic droplets, diverting lipids from the 
VLDL assembly pathway. We also observed that epigal-
locatechin gallate, which is present in green tea, increases 
the rate of fusion between droplets, resulting in an increased 
pool of cytosolic lipid droplets, and decreases the assembly 
and secretion of VLDL, in particular VLDL1 (Li et al 2006). 
Together, these results indicate that factors that promote the 
assembly of lipid droplets and increase their cellular pool can 
in fact deplete the VLDL assembly pathway of lipids and 
thus decrease the secretion of the lipoprotein.
It is known that the secretion of VLDL1 is reduced by 
insulin (see Taskinen 2003) for review). Moreover, a failure 
of this insulin effect may be of importance for the formation 
of the dylipidemia seen in insulin resistance and type 2 diabe-
tes. The mechanism is not understood, but it is possible that 
promotion of lipid droplet assembly by insulin (Andersson 
et al 2006) promotes a shift of triglycerides from the VLDL 
assembly pathway to storage in cytosol. There are, however, 
other tentative mechanisms to explain the inﬂ  uence of insulin 
on VLDL assembly (for review, see (Taskinen 2003)).
Post-translational regulation 
of the secretion of apoB100
The secretion of apoB100 is regulated post-transcriptionally 
by co- and post-translational degradation. It has long been 
known that apoB100 undergoes intracellular degradation 
(for review, see (Olofsson et al 1999; Davidson and Shelness 
2000; Shelness and Sellers 2001)). The intracellular degrada-
tion of apoB100 occurs at three different levels (Fisher and 
Ginsberg, 2002; Fisher et al 2001):
(i)   Close to the biosynthesis of apoB (co- or post-transla-
tionally) by a mechanism that involves retraction of the 
apoB molecule from the lumen of the ER to the cytosol, a 
ubiquitination and a subsequent proteasomal degradation 
(Mitchell et al 1998; Liang et al 2000; Fisher et al 2001; 
Pariyarath et al 2001). The co-translational degradation 
Figure 3 (A) Lipid droplets are formed as primordial droplets at the microsomal 
membranes. Insulin stimulates the droplet formation by activating PLD1 and ERK2. 
ERK2 phosphorylates the motor protein dynein, which is then recruited to the drop-
lets to promote their formation and fusion. Diacylglycerol acyltransferase (DGAT) 
catalyzes the formation of triglycerides (TG) from diglycerides (DG) and fatty acids 
(FA). It has been suggested that the lipid droplet is initiated by the oiling out of tri-
glycerides between the leaﬂ  ets of the membrane. (B) Primordial droplets increase in 
size by fusion. This process depends on dynein and its interaction with microtubules. 
Moreover it involves speciﬁ  c proteins that catalyze fusion between the droplets.Vascular Health and Risk Management 2007:3(4) 496
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poorly understood. Several hypotheses have been articulated 
to explain the events that initiate atherogenesis: the response-
to-injury hypothesis states that endothelial injury leads to 
an inﬂ  ammatory response as a part of a healing process in 
the arterial wall (Ross 1999; Ross et al 1977); the response-
to-oxidation hypothesis proposes that lipoprotein oxidation is 
the important link in atherosclerosis (Steinberg et al 1989); and 
the response-to-retention hypothesis suggests that subendothe-
lial retention of lipoproteins is the initiating step and leads to 
oxidation, inﬂ  ammation, and endothelial dysfunction (Williams 
and Tabas 1995; Williams and Tabas 1998). This hypothesis 
is based on pioneering work from the 1970s and 1980s show-
ing that lipoproteins can interact with the arterial wall (Iverius 
1972; Camejo et al 1975; Vijayagopal et al 1981).
While these hypotheses are by no means mutually 
exclusive, and may even be considered mutually compatible 
with differences in emphasis, a growing body of recent 
evidence supports the response-to-retention hypothesis. This 
hypothesis states that the subendothelial retention of lipo-
proteins determines the concentration and the susceptibility 
to modiﬁ  cation of lipo  proteins in the arterial wall. Several 
lines of evidence indicate that the retention of arterial lipo-
proteins involves the extracellular matrix, and proteo glycans 
in particular appear to play an important role.
Mechanism for retention 
of atherogenic lipoproteins in the 
artery wall
The binding of atherogenic lipoproteins to artery wall proteo-
glycans is mediated by ionic interactions between clustered 
basic amino acids in the apoB100 that bind to the negatively 
charged glycosaminoglycans (GAGs) of the proteoglycans. 
In vitro studies of delipidated apoB100 identiﬁ  ed eight 
speciﬁ  c regions of clustered basic amino acids in the apoB 
moiety of LDL that bind to the negatively charged GAGs 
(Hirose et al 1987; Weisgraber and Rall Jr, 1987; Camejo 
et al 1988). However, it was not known which of these sites 
were functional on LDL particles. To identify the main pro-
teoglycan-binding sites on LDL, speciﬁ  cally mutated forms 
of the human apoB gene were expressed in transgenic mice, 
and the ability of the recombinant human LDL isolated from 
the mice to bind to artery wall proteoglycans in vitro was as-
sessed (Boren et al 1998b). These experiments implicated the 
basic amino acids in Site B (residues 3359–3369; Figure 1), 
the site in apoB100 that binds to the LDL receptor, as the 
main site on apoB100 that interacts with proteoglycans 
(Boren et al 1998b). In addition, a mutant recombinant LDL 
of apoB is inﬂ  uenced by the availability of lipids and 
the activity of MTP. Thus, when the amount of lipids or 
the MTP activity is limited, apoB100 remains associated 
with the translocon and is sorted to proteasomal degrada-
tion (for review, see (Fisher and Ginsberg 2002)). It is 
well known that secretory proteins that misfold undergo 
proteasomal degradation (see above; Figure 2). A lack of 
lipids may remove one of the prerequisites for the correct 
folding of apoB, thus promoting its degradation.
(ii)    Post-translationally by an unknown mechanism that 
can be promoted by culturing the cells in the presence 
of polyunsaturated fatty acids (Fisher et al 2001). This 
degradation seems to occur in a compartment separate 
from the rough ER, and has therefore been referred to 
as post-ER presecretory proteolysis (PERPP) (Fisher et 
al 2001). Nothing is known about the enzyme systems 
involved or the sorting of apoB100 for this degrada-
tion. The process is promoted by ω-3 fatty acids and 
by increased levels of reactive oxygen species (Jiang et 
al 2005). It has also been demonstrated that apoB100 
interacts with the protease/chaperone ER 60 (Adeli et al 
1997; Taghibiglou et al 2002), and that this interaction is 
linked to the intracellular degradation of newly synthe-
sized apoB100. The role of this interaction for PERPP 
has not been elucidated.
(iii) By reuptake from the unstirred water layer around the 
outside of the plasma membrane (Williams et al 1990) 
via the LDL receptor. The LDL receptor has been shown 
to have an important role in regulation of the secretion 
of apoB100-containing lipoproteins (Horton et al 1999; 
Twisk et al 2000). There is even evidence that the effect 
of the receptor is not only due to the interaction with 
apoB100 on the cell surface, but that the receptor and 
apoB100 interact early in the secretory pathway and that 
this interaction is of importance for the post-translational 
degradation of apoB100 (Gillian-Daniel et al 2002; Lars-
son et al 2004; Twisk et al 2000)}.
The apoB100 primordial particle (pre-VLDL) is not 
secreted from the cell to any signiﬁ  cant extent, but appears 
to be retained and degraded (unless converted to VLDL2; 
see above) (Stillemark-Billton et al 2005)
The development of atherosclerosis: 
different hypotheses
Although it is well documented that elevated levels of LDL 
and other apoB-containing lipoproteins cause increased 
atherosclerosis, the molecular and cellular mechanisms for 
the pathobiological changes that lead to the disease are still Vascular Health and Risk Management 2007:3(4) 497
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with a single amino acid mutation (K3363E) was generated 
that bound normally to the LDL receptor but defectively to 
proteoglycans (Boren et al 1998b). This ﬁ  nding showed that it 
is possible to discriminate between the LDL receptor-binding 
activity and proteoglycan-binding activity, even though 
their binding sites coincide (Boren et al 1998a; Boren et al 
1998b). These and other experiments also indicate that the 
LDL receptor binding is conformational dependent, whereas 
proteoglycan-binding is charge dependent.
Atherosclerosis studies in mice 
expressing recombinant LDL
The atherogenic potential of the interaction between 
apoB100 and artery wall proteoglycans was investigated in 
transgenic mice expressing human control LDL and recom-
binant proteoglycan-binding-defective LDL (ie, LDL with a 
Site B mutation that abolishes the binding to proteoglycan) 
(Skalen et al 2002). The study was designed to ensure that 
any differences in atherosclerosis were due to weak binding 
of the proteoglycan-binding-defective LDL to proteoglycans 
and not to some other attribute of the mutated LDL, such as 
the inability to bind to LDL receptors.
The transgenic mice were fed a Western diet for 20 
weeks. The results showed that the extent of the vessel 
wall covered by atherosclerotic lesions correlated with the 
plasma cholesterol level in both groups of transgenic mice. 
However, the extent of atherosclerosis differed dramatically. 
Transgenic mice expressing the proteoglycan-binding-de-
fective LDL had strikingly less atherosclerosis than mice 
expressing wild-type recombinant LDL. These ﬁ  ndings show 
that proteoglycan-binding-defective LDL has a greatly re-
duced atherogenic potential and provide direct experimental 
evidence that binding of LDL to artery wall proteoglycans is 
an early step in atherogenesis (Skalen et al 2002).
A tentative explanation for why some atherosclerosis 
developed in mice that express proteoglycan-binding-defective 
apoB is that LDL from mice on a high-fat diet contains apoE, 
which can mediate binding to proteoglycans and thus reten-
tion. Indeed, proteoglycan-binding-defective LDL isolated 
from the mice in the atherosclerosis study contained apoE 
and displayed approximately 20% of normal proteoglycan 
binding (Skalen et al 2002).
Is it possible to modulate the 
proteoglycan binding of LDL?
The conformation of apoB100 on the surface of the LDL 
particle is dependent on the composition of the core lipids, 
the surface phospholipid content, and the diameter of the 
lipoprotein particle. Thus, binding sites other than Site B 
may become functional in modiﬁ  ed LDL. LDL that has been 
modiﬁ  ed by secretory group IIA phospholipase A2 (sPLA2), a 
strong risk factor for coronary heart disease (Kugiyama et al 
1999), binds to proteoglycans more avidly than unmodiﬁ  ed 
LDL (Sartipy et al 1998). Recent studies have shown that 
Site A (residues 3147–3157 in apoB100) becomes functional 
in modiﬁ  ed forms of LDL and that it then acts cooperatively 
with Site B in the association with proteoglycans (Flood et al 
2004). Furthermore, the core lipids of LDL also inﬂ  uence 
the folding of apoB100 on the LDL particle. Recent studies 
have shown that the triglyceride content of LDL inﬂ  uences 
the conformation of apoB and decreases the afﬁ  nity for 
GAGs. This mechanism is mediated by a conformational 
change of Site B and is, in contrast to sPLA2-modiﬁ  ed LDL, 
independent of Site A (Flood et al 2004). The ﬁ  nding that the 
triglyceride content of LDL decreases the binding of LDL to 
artery wall proteoglycans may explain why triglyceride-rich 
apoB LDL are not as atherogenic as the triglyceride poor 
(Willner et al 2003).
Indirect interactions of LDL to the 
extracellular matrix
In addition to the direct interaction between apoB100 and 
artery wall proteoglycans, retention of LDL also appears to 
involve an indirect interaction between LDL and artery wall 
proteoglycans facilitated by “bridging molecules”. ApoE 
functions as a potent bridging molecule between recombinant 
LDL and artery wall proteoglycans, and apoE enrichment 
of proteoglycan-binding-defective LDL substitutes for the 
defective direct interaction between RK3359–3369SA LDL 
and artery wall proteoglycans (Skalen et al 2002).
In addition to apolipoproteins, several lipases have 
been shown to mediate bridging between lipoproteins and 
heparin sulfate proteoglycans (HSPGs) on the cell surface, 
which results in increased cellular uptake and degradation 
of lipoproteins. Lipoprotein lipase (LPL), which is secreted 
by smooth muscle cells and macrophages in atherosclerotic 
lesions (Boren et al 2001b), has been shown to act as a bridge 
between GAG and extensively oxidized LDL, which is suf-
ﬁ  ciently depleted of positive charges to inhibit direct binding 
to GAG (Olin et al 1999; Pentikainen et al 2000).
Thus, the proteoglycan-binding activity of LDL depends 
on the diameter and lipid composition of the LDL particle 
and on the presence of apolipoproteins other than apoB 
on the LDL particle. Several pathological conditions with Vascular Health and Risk Management 2007:3(4) 498
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macrophages, but also in Kupffer cells and hepatocytes; by 
contrast, little or no accumulation was observed in these cells 
in human ABCG1 transgenic mice (Baldan et al 2006b).
Interestingly, ABCG1 is important for the exit of cho-
lesterol to HDL but not to lipid-poor apoA-1 (for review, 
see (Baldan et al 2006b)). Indeed, it has been suggested 
that ABCA1 and ABCG1 work in concert. Thus, ABCA1 
is suggested to lipidate lipid-poor apoA-I while ABCG1 
promotes the efﬂ  ux of cholesterol to the already preformed 
lipid–protein complexes (Gelissen et al 2006; Vaughan and 
Oram 2006). However, there are suggestions that ABCA1 
and ABCG1 control separate cholesterol efﬂ  ux pathways 
(for review, see (Baldan et al 2006b)). There are diverging 
opinions about the importance of ABCG1 for the develop-
ment of atherosclerosis (Baldan et al 2006a; Out et al 2006; 
Ranalletta et al 2006), but a recent paper seems to favour the 
idea that ABCG1 protects against the development of this 
disease (Out et al 2007).
Nascent HDL is modiﬁ  ed in plasma by several factors. 
The most well known is lecithin cholesterol acyltransferase 
(LCAT), which esteriﬁ  es cholesterol allowing the forma-
tion of a core in the lipoprotein. The core of HDL is also 
modiﬁ  ed by cholesterol ester transfer protein (CETP), which 
exchanges cholesterol and triglycerides between HDL and 
triglyceride-rich lipoproteins such as VLDL. Phospholipids 
are also transferred from the surface of triglyceride-rich 
lipoprotein (during triglyceride hydrolyses) to HDL.
The catabolism of HDL can occur in at least two ways: (i) 
by selective removal of cholesterol and other lipids without 
uptake of the whole particle (this involves the scavenger 
receptor B1); and (ii) by uptake and degradation of the 
whole particle, which involves endocytosis and lysosomal 
degradation.
ApoAI and HDL are highly linked to the so-called reverse 
cholesterol transport, ie, the transfer of cholesterols from 
peripheral cells to the liver to be secreted as bile acids. The 
roles of ABCA1, ABCG1 and the scavenger receptor B1 in 
the turn over of HDL seem to ﬁ  t very well into such a role 
of HDL. However, the process is far from elucidated and 
may be complex. In humans, radiolabeled HDL cholesterol 
that is eventually secreted into the bile is almost entirely 
transported to apoB-containing lipoproteins (presumably 
through CETP).
Apolipoprotein levels in plasma 
as a tool for clinical judgements
In most clinical trials on lipid lowering for prevention of 
cardiovascular disease, LDL cholesterol has been used both 
increased risk of cardiovascular diseases, such as diabetes 
and rheumatoid arthritis, are characterized by LDL particles 
with enhanced interaction with the subendothelium (Hurt-
Camejo et al 2001; Nesto and Rutter 2002)
The assembly and metabolism 
of HDL
Another important player in atherogenesis is HDL and its 
major apolipoprotein apoA1. Amphipatic α-helices anchor 
apoAI in the surface of the HDL particles. In contrast to 
apoB100, apoAI can transfer between particles.
The assembly and metabolism of HDL have recently been 
extensively reviewed (see for example (Lewis and Rader 
2005; Yokoyama 2005 Krimbou et al 2006)), and here we 
will only deal brieﬂ  y with this subject. A groundbreaking 
event in the understanding of the assembly of HDL was the 
identiﬁ  cation of the gene for Tangiers disease (Bodzioch et al 
1999; Brooks-Wilson et al 1999; Marcil et al 1999; Remaley 
et al 1999; Rust et al 1999), a condition in which HDL is 
almost completely lacking. This gene was shown to encode 
the ATP-binding cassette transporter (ABCA1), which is 
involved in supplying lipid-poor apoAI or pre-β-HDL with 
cholesterol.
It is now believed that apoAI is secreted from liver 
and intestine as lipid-poor apoAI (for recent reviews, see 
for example (Krimbou et al 2006; Lewis and Rader 2005; 
Yokoyama 2005)) . Lipid-poor apoAI seems to be the major 
target for the lipidation by ABCA1; the transporter is critical 
for the initial lipidation of apoAI, protecting it from being 
rapidly degraded in the liver, kidney, and steroidogenic cells. 
The lipidation of apoAI by ABCA1 is a complex process 
that is not understood in detail, but is thought to involve an 
interaction between the apolipoprotein and the transporter 
and the formation of a high-afﬁ  nity binding site for apoAI 
from which the nascent pre-β-HDL is formed. The process 
involves intracellular cAMP release induced by apoAI and 
phosphorylation of ABCA1 by protein kinase A. It also 
appears that the apoAI–ABCA1 complex can be internalized 
and transported through early and late endosomes (and pos-
sibly through other unknown compartments), during which 
time nascent HDL is formed and secreted.
In addition to ABCA1, transporters of the ABCG family 
play an essential role in the efﬂ  ux of cellular cholesterol to 
HDL (Klucken et al 2000; Kennedy et al 2005). ABCG1 
has been reviewed recently (Baldan et al 2006b; Oram and 
Vaughan 2006) and it seems to primarily inﬂ  uence the cho-
lesterol content of macrophages. In ABCG1-/- mice, high 
levels of neutral lipids accumulated particularly in pulmonary Vascular Health and Risk Management 2007:3(4) 499
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as a target for treatment and for the identiﬁ  cation of treatment 
success. This relates to trials using drugs as well as dietary 
intervention. Consequently, the different guidelines for 
prevention of cardiovascular disease have LDL levels as 
their primary target (2005; Conroy et al 2003; Grundy et al 
2004). With the increased efﬁ  ciency of lipid-lowering drugs, 
it has also become evident that targets far below the earlier 
suggested goals for LDL cholesterol may further reduce the 
morbidity and mortality in cardiovascular disease.
Recently, apoB as a target for treatment has been 
widely discussed and also supported by authorities in 
some guidelines (Grundy 2002; Genest et al 2003). ApoB 
in plasma is regarded as a marker for the total number of 
atherogenic lipoproteins in plasma, and the equivalent in 
lipid terms would be non-HDL cholesterol. Non-HDL 
cholesterol is also given as an alternative treatment goal 
in the National Cholesterol Education Program (NCEP) 
(Clearﬁ  eld 2003). Although strongly correlated, however, 
apoB and non-HDL cholesterol are not identical, and sev-
eral studies have found that apoB is a better predictor of 
risk for cardiovascular disease than non-HDL cholesterol 
(for review, see (Sniderman et al 2003).
It has been suggested that apoB could substitute for LDL 
cholesterol and non-HDL cholesterol for risk prediction 
(Pischon et al 2005). However, this idea has been questioned 
because the currently available population and disease cor-
relation data and the cholesterol education program are 
based on LDL cholesterol and non-HDL cholesterol (Denke 
2005). It is important to note that apoB is a direct measure of 
particle number rather than lipid content, which is a crucial 
point for patients with the metabolic syndrome or type 2 
diabetes. These subjects often have increased levels of small 
dense LDL, which are not detected by a simple lipid analysis. 
Thus, the combination of hypertriglyceridemia and high 
apoB is a new important risk algorithm (Sniderman 2004). 
Few intervention studies have been designed to use apoB 
levels for inclusion or as treatment target. However, data 
from some of the large statin trials indicate that apoB could 
also serve as an important treatment goal. For example, in 
the AFCAPS/TexCAPS trial, apoB in subjects on treatment 
was a strong predictor for major coronary events, both in the 
actively treated and the placebo groups (Gotto et al 2000).
Levels of ApoAI in plasma are strongly correlated with 
HDL levels. In agreement with the studies on HDL, low 
apoAI has been shown to be equivalent or better than low 
HDL cholesterol as a risk marker for atherosclerosis or 
cardiovascular events (Francis and Frohlich 2001; Luc et al 
2002; Walldius and Jungner 2006). Several mechanisms 
to explain the strong association between low apoAI and 
risk have been suggested (Barter and Rye 2006). The most 
common is that apoAI has an important role in the reversed 
cholesterol transport, and an alternative suggestion is that 
apoAI is anti-inﬂ  ammatory or an antioxidant (for review see 
(Barter and Rye 2006). However, the process is not convinc-
ingly understood.
It is more complex to determine whether elevation of 
apoAI also can be used as a target for treatment. ApoAI levels 
in plasma reﬂ  ect both production and clearance. Interference 
in these processes may have opposing effects on the reverse 
cholesterol transport. In recent studies in humans and animal 
models, infusions of HDL or apoAI resulted in reduced athero-
sclerosis (Nissen et al 2003; Nicholls et al 2005), suggesting 
that increased plasma levels of apoAI or HDL have the 
potential to treat and prevent atherosclerosis.
A lot of enthusiasm has recently been focused on the apoB/
apoAI ratio as a risk marker or treatment target. Several large 
epidemiological studies strongly support this concept by ﬁ  nd-
ing the apoB/apoAI ratio superior to lipid parameters as a risk 
marker (for review see (Walldius and Jungner 2006). Whether 
the ratio apoB/apoAI also can be used as a general treatment 
target still has to be proven. It seems unlikely that a high ratio 
caused by low apoAI should be treated the same way as a low 
ratio caused by high apoB. Furthermore, we do not know if a 
change in the ratio caused by apoB reduction is equivalent to 
an increase in apoAI. This has to be further studied, but the 
treatment should be based on levels of both apoB and apoAI, 
and probably also on LDL and HDL lipid levels.
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